Free Trial

Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Up - What's Next?

Daiichi Sankyo logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • Shares gapped up pre-market, opening at $19.71 vs the prior close of $18.97 and last trading near $19.02, up about 0.9% on a volume of 19,545 shares.
  • Q4 results were mixed: EPS beat estimates ($0.30 vs $0.25) while revenue missed ($3.65B vs $3.88B), with a net margin of 14.83% and ROE of 18.64%.
  • Valuation and technicals: market cap ~$36.25B, P/E ~17.6 and PEG 1.09; 50‑day SMA $19.12 vs 200‑day SMA $22.00, and analysts expect about 0.73 EPS for the year.
  • Five stocks we like better than Daiichi Sankyo.

Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY - Get Free Report) gapped up before the market opened on Tuesday . The stock had previously closed at $18.97, but opened at $19.71. Daiichi Sankyo shares last traded at $19.02, with a volume of 19,545 shares trading hands.

Daiichi Sankyo Stock Up 0.9%

The firm has a market capitalization of $36.25 billion, a P/E ratio of 17.56, a price-to-earnings-growth ratio of 1.09 and a beta of -0.35. The company has a current ratio of 2.69, a quick ratio of 1.85 and a debt-to-equity ratio of 0.18. The company's fifty day simple moving average is $19.12 and its 200 day simple moving average is $22.00.

Daiichi Sankyo (OTCMKTS:DSNKY - Get Free Report) last announced its quarterly earnings data on Thursday, January 29th. The company reported $0.30 EPS for the quarter, beating the consensus estimate of $0.25 by $0.05. The company had revenue of $3.65 billion for the quarter, compared to the consensus estimate of $3.88 billion. Daiichi Sankyo had a net margin of 14.83% and a return on equity of 18.64%. Research analysts expect that Daiichi Sankyo Co., Ltd. - Sponsored ADR will post 0.73 EPS for the current year.

Daiichi Sankyo Company Profile

(Get Free Report)

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Daiichi Sankyo Right Now?

Before you consider Daiichi Sankyo, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Daiichi Sankyo wasn't on the list.

While Daiichi Sankyo currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines